Skip to main content

Myositis

Clinical Profiles Seen with NXP-2 Antibodies A recent review of the myositis associated autoantibody NXP-2 profiles its clinical associations with dermatomyositis (DM), calcinosis, severe myositis and, in some reports, with cancer. https://t.co/oCgb1f2Avw https://t.co/rnMa4jHhNy
Clinical Profiles Seen with NXP-2 Antibodies A recent review of the myositis associated autoantibody NXP-2 profiles its clinical associations with dermatomyositis (DM), calcinosis, severe myositis and, in some reports, with cancer. https://t.co/DTNohe66n1 https://t.co/Bu1qbi5Q1q
antibody (Keep)

Clinical Profiles Seen with NXP-2 Antibodies

Sep 20, 2022

A recent review of the myositis associated autoantibody NXP-2 profiles its clinical associations with dermatomyositis (DM), calcinosis, severe myositis and, in some reports, with cancer.

Read Article
EULAR/ACR Classification in MDA5+ Myositis Patients A current analysis suggests that nearly 30% of MDA5 IIM patients may be missed by the 2017 EULAR/ACR classification criteria for IIM.https://t.co/rS25rL5fGO https://t.co/Yw7sGmPW5G
RheumNow Podcast square

Goofy But True

Sep 02, 2022

Dr. Jack Cush discusses declining survival rates in the USA, FDA approvals of new COVID subvariant boosters and other odd and possibly true new research reports from the past week on RheumNow.com.




  1. After historic drop in 2020 (COVID), life expectancy in USA dropped again,

Read Article
myositis, polymyositis, wikipedia

EULAR/ACR Classification in MDA5+ Myositis Patients

The diagnosis of idiopathic inflammatory myopathies (IIMs) can be informed by the 2017 EULAR/ACR classification criteria, but their utility in patients with clinically amyopathic dermatomyositis (CADM) and anti–melanoma differentiation–associated protein 5 (anti–MDA-5)–positive IIM is less

Read Article
Approach to ILD in Myositis Syndromes Mehta et al have published a full read review of managing ILD in patients with inflammatory myopathies, a heterogeneous group of syndromes connected by ILD and and increased morbidity and mortality risk.https://t.co/MLBGL2ZqTk https://t.co/cdO2nHAK6h
Lungs ILD

Approach to ILD in Myositis Syndromes

Jul 28, 2022

Mehta et al have published a full read review of managing interstitial lung disease (ILD) in patients with inflammatory myopathies, a heterogeneous group of syndromes connected by ILD and and increased morbidity and mortality risk.



They divide myositis-ILD into three main prognostic

Read Article
RheumNow Podcast square

Fever Pitch (7.15.2022)

Jul 15, 2022

Dr. Jack Cush reviews the new studies and drug approvals and new insights into febrile disorders from the past week on RheumNow.com




  1. Ustekinumab (IL-12/23i) phase 2 study was successful in #SLE; but the phase 3 LOTUS study of 512 pts, UST was NOT superior to PBO (SRI-4 44% v

Read Article
2021,year

ICYMI: 2021 Rheumatology Year in Review

Jul 08, 2022

For 2022, let's look our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
🆕🚨Possible future avenues for myositis therapeutics: DM,IMNM&IBM Current treatment options in IIM management 1st line:GC+ Skin➡️MTX/AZR/MMF Muscle➡️AZR/MMF/MTX Lung➡️AZR/MMF Dysphagia/Diaphragmatic weakness➡️IVIG RP-ILD➡️IVIG+CNI+CYC/RTX Calcinosis➡️JAKihttps://t.co/G3vN055Gyq https://t.co/Qy9MULgeMs
Full read review of Inclusion body myositis: an untreatable, slowly progressive muscle disorder seen w/ aging; distinctive pattern of weakness involving the quadriceps and finger flexor muscles, w/ certain genetic predispositions https://t.co/BxwyTacnZF https://t.co/c4wDkX6Yi9
Dr Aggarwal @docrota et al. Abatacept RCT in IIM. Overall negative trial. Pre-specified and post-hoc analyses suggest some benefit in PM/ANM but not in DM @RheumNow #EULAR2022 POS0839 https://t.co/uttMLKy9fW
Sousa et al. Anti-Ku disease. Cluster analysis (Ku alone, Ku with other abs) asking is is a distinct entity. In isolated anti-Ku+ maybe so, characterised by Raynauds (41%), arthritis (26%), sicca (26%), myositis (15%), ILD (15%) @RheumNow #EULAR2022 POS0861 https://t.co/IboWzMYFMB
✨ Inflammatory #Myositis✨ 👉 Excellent summary of Autoantibodies, Immune alterations and Distinct Phenotypes by Dr. Lisa Rider #EULAR2022 https://t.co/KLzmLUGk9Z
Patient,instruction

Making You the Expert of You! (Smart Rules for Patients)

May 10, 2022

You’ve scheduled an appointment with your medical provider - how do you make the most of it? We've gathered these tips and suggestions to share with patients.

Read Article
myositis.jpg

BSR Guideline on Idiopathic Inflammatory Myopathy

May 05, 2022

The British Society of Rheumatology (BSR) has published evidence-based guidelines for idiopathic inflammatory myopathy (IIM) affecting juvenile and adult-onset disease. This rare condition has an estimated prevalence of 5-15 per 100,000 persons.

Read Article
RheumNow Podcast square

Male vs. Female Responders (4.15.2022)

Apr 15, 2022

Dr. Jack Cush reviews the news and journal Reports from the past week on RheumNow.com - including fellowship COVID-19 concerns, the limits of T2T in gout and the real odds of RA remission with your first biologic. 




  1. Downward Effects! Real world data from 22,934 UK #RA pts

Read Article
cancer, melanoma, metastatic, cell

Increased Cancer Risk with Autoimmune Disorders

Mar 31, 2022

The incidence and mortality of cancer among autoimmune diseases (AID) was studied in a large Chinese cohort, demonstrating that while onset time and risks vary, there is an increased risk of malignancy in AID.



The cohort included 8,120 AID patients from a national tertiary referral

Read Article
RheumNow Podcast square

RheumNow Live is Coming to Town (3.11.2022)

Mar 11, 2022

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
myositis.jpg

Predicting Treatment Response in Inflammatory Muscle Disorders

MedPage Today
Feb 17, 2022

Rheumatologists looking for clues to whether their patients with certain inflammatory myopathies will improve on immunosuppressive drugs may find them in a new study appearing in Arthritis Care & Research.



Presence of dermatomyositis-specific autoantibodies, shorter time between

Read Article
CV,risk,MI,heart,cardiac

CV Risk Management in Rheumatic Disease Patients

Feb 15, 2022

The European League against Rheumatism (EULAR) has developed recommendations for cardiovascular risk (CVR) management in rheumatic disease patients based on literature review and expert consensus.



These recommendations are applicable to patients with gout, vasculitis, systemic

Read Article
RheumNow Podcast square

Hand OA and Heroes in Rheumatology (2.11.2022)

Feb 11, 2022

Interesting reports this week about dementia, who gets hand OA and a great list of women Heroes and Pillars of Rheumatology. Tune in as Dr. Jack Cush reviews the news and journal articles from this past week in RheumNow.com.

Read Article
vaccine.jpg

Hold Myophenolate or Not with COVID-19 Vaccination?

Jan 13, 2022

While the American College of Rheumatology recommends holding mycophenolate (MMF) in rheumatic and musculoskeletal diseases patients (RMD) receiving COVID-19 vaccines, there is limited data on such an approach. A recent cohort study of RMD patients showed that holding MMF yielded higher antibody

Read Article
2021,year

2021 Rheumatology Year in Review

Jan 08, 2022

Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
×